Page last updated: 2024-10-29
ketanserin and Habit Chorea
ketanserin has been researched along with Habit Chorea in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| "Twenty adults with Tourette's syndrome and 20 healthy control subjects were investigated with PET-[18F]altanserin using a bolus-infusion protocol." | 1.34 | Cerebral 5-HT2A receptor binding is increased in patients with Tourette's syndrome. ( Bolwig, TG; Hansen, ES; Haugbøl, S; Knudsen, GM; Nielsen, FA; Pinborg, LH; Regeur, L; Skovgaard, LT; Svarer, C, 2007) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Haugbøl, S | 1 |
| Pinborg, LH | 1 |
| Regeur, L | 1 |
| Hansen, ES | 1 |
| Bolwig, TG | 1 |
| Nielsen, FA | 1 |
| Svarer, C | 1 |
| Skovgaard, LT | 1 |
| Knudsen, GM | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome[NCT04794413] | Early Phase 1 | 10 participants (Actual) | Interventional | 2018-11-12 | Completed |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Other Studies
1 other study available for ketanserin and Habit Chorea